CFO4Life Group’s Lam Research LRCX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.23M | Buy |
2,834
+173
| +7% | +$52.5K | 0.17% | 69 |
|
|
2026
Q1 | $569K | Sell |
2,661
-1,067
| -29% | -$239K | 0.09% | 114 |
|
|
2025
Q4 | $638K | Buy |
3,728
+1,440
| +63% | +$224K | 0.09% | 103 |
|
|
2025
Q3 | $306K | Buy |
+2,288
| New | +$242K | 0.04% | 168 |
|
|
2024
Q3 | – | Sell |
-10,740
| Closed | -$1.14M | – | 223 |
|
|
2024
Q2 | $1.14M | Sell |
10,740
-140
| -1% | -$13.4K | 0.22% | 59 |
|
|
2024
Q1 | $1.06M | Sell |
10,880
-2,020
| -16% | -$178K | 0.19% | 61 |
|
|
2023
Q4 | $1.01M | Sell |
12,900
-1,240
| -9% | -$84.5K | 0.19% | 66 |
|
|
2023
Q3 | $886K | Sell |
14,140
-620
| -4% | -$40.7K | 0.2% | 61 |
|
|
2023
Q2 | $949K | Sell |
14,760
-940
| -6% | -$53K | 0.2% | 57 |
|
|
2023
Q1 | $832K | Buy |
15,700
+480
| +3% | +$23.6K | 0.19% | 59 |
|
|
2022
Q4 | $640K | Sell |
15,220
-810
| -5% | -$33.9K | 0.14% | 89 |
|
|
2022
Q3 | $587K | Sell |
16,030
-210
| -1% | -$9.35K | 0.16% | 75 |
|
|
2022
Q2 | $687K | Buy |
16,240
+810
| +5% | +$38.6K | 0.17% | 63 |
|
|
2022
Q1 | $829K | Sell |
15,430
-980
| -6% | -$57K | 0.17% | 62 |
|
|
2021
Q4 | $1.18M | Buy |
16,410
+1,950
| +13% | +$122K | 0.24% | 47 |
|
|
2021
Q3 | $823K | Buy |
14,460
+180
| +1% | +$10.9K | 0.19% | 57 |
|
|
2021
Q2 | $929K | Buy |
14,280
+220
| +2% | +$13.9K | 0.21% | 53 |
|
|
2021
Q1 | $837K | Sell |
14,060
-1,900
| -12% | -$104K | 0.21% | 53 |
|
|
2020
Q4 | $754K | Sell |
15,960
-800
| -5% | -$33.7K | 0.22% | 53 |
|
|
2020
Q3 | $556K | Buy |
16,760
+3,350
| +25% | +$115K | 0.19% | 59 |
|
|
2020
Q2 | $434K | Sell |
13,410
-10,330
| -44% | -$282K | 0.17% | 63 |
|
|
2020
Q1 | $570K | Sell |
23,740
-5,650
| -19% | -$163K | 0.3% | 46 |
|
|
2019
Q4 | $859K | Sell |
29,390
-1,900
| -6% | -$50.5K | 0.36% | 46 |
|
|
2019
Q3 | $723K | Sell |
31,290
-3,010
| -9% | -$63.2K | 0.32% | 46 |
|
|
2019
Q2 | $644K | Buy |
34,300
+340
| +1% | +$6.45K | 0.29% | 50 |
|
|
2019
Q1 | $608K | Sell |
33,960
-7,510
| -18% | -$125K | 0.28% | 53 |
|
|
2018
Q4 | $565K | Sell |
41,470
-780
| -2% | -$11.2K | 0.25% | 59 |
|
|
2018
Q3 | $641K | Buy |
42,250
+2,740
| +7% | +$46.8K | 0.28% | 58 |
|
|
2018
Q2 | $683K | Sell |
39,510
-4,650
| -11% | -$89.6K | 0.29% | 52 |
|
|
2018
Q1 | $897K | Sell |
44,160
-910
| -2% | -$18K | 0.76% | 16 |
|
|
2017
Q4 | $830K | Sell |
45,070
-1,500
| -3% | -$29.5K | 0.65% | 20 |
|
|
2017
Q3 | $862K | Sell |
46,570
-610
| -1% | -$9.9K | 0.7% | 18 |
|
|
2017
Q2 | $667K | Sell |
47,180
-9,380
| -17% | -$138K | 0.61% | 23 |
|
|
2017
Q1 | $726K | Buy |
+56,560
| New | +$665K | 0.66% | 21 |
|
Other funds holding LRCX
CFO4Life Group's LRCX Position: Q2 2026 in Review
CFO4Life Group increased its Lam Research (LRCX) stake by 6.5% in Q2 2026, buying an estimated $52.5K and bringing the position to 2,834 shares worth $1.23M. The position accounts for 0.17% of the portfolio, ranked #69.
CFO4Life Group first reported a position in LRCX in Q1 2017 and has held it in 34 quarters since. 3,118 funds tracked by Wall St. Rank hold LRCX as of Q2 2026.
- CFO4Life Group held 2,834 shares of Lam Research worth $1.23M as of Q2 2026.
- CFO4Life Group bought 173 Lam Research shares in Q2 2026, an estimated $52.5K.
- Lam Research made up 0.17% of CFO4Life Group's portfolio in Q2 2026, its #69 holding.
- CFO4Life Group first reported a position in Lam Research in Q1 2017 and has held it in 34 quarters since.
- 3,118 funds tracked by Wall St. Rank held Lam Research as of Q2 2026.
Based on CFO4Life Group's 13F filing for Q2 2026, filed 12 Aug 2026.